20 August 2024
Hogan Lovells advises MorphoSys on its delisting from the stock exchange and the public delisting tender offer by Novartis
Advising firms
Deal team
2 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Prof. Dr. Michael Schlitt Lead | Hogan Lovells Cadwalader | Partner | Not stated | Frankfurt |
| Dr Sebastian Biller Lead | Hogan Lovells Cadwalader | Counsel | Not stated | Munich |
Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- EUR 68 (EUR 68.00 per MorphoSys share)
- What the figure measures
- Per share
- Client
- MorphoSys AGTarget
- Counterparties
- Novartis (Buy-side)